Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

The Effect of Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors (TKI) on Clinical Outcomes Among Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received First-Line Sunitinib in the International mRCC Database Consortium (IMDC) Based on Prognostic Risk Score

This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.

Clear cell mRCC patients who initiated sunitinib as first-line treatment between 2010 and 2018 were identified from the IMDC database. Patients were classified as favorable, intermediate, or poor prognostic risk group according to IMDC criteria. Overall survival, time to treatment discontinuation, and physician-assessed tumor response were evaluated.

Inclusion Criteria:

• Diagnosed with mRCC
• Initiated treatment post mRCC diagnosis and received sunitinib as first-line therapy
• Age 18 years or over at the time of mRCC diagnosis
• Actively treated at an IMDC clinical center

Exclusion Criteria:

• Initiated first line sunitinib treatment before 2010
• Had non-clear cell mRCC